Trial Profile

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (AVONELLE-X)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 26 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Faricimab (Primary)
Indications Wet age-related macular degeneration
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms AVONELLE-X
Sponsors Roche

Most Recent Events

21 Oct 2030 This profile has been reviewed under High Value Profile, Ad Hoc Task.
05 Sep 2025 Results presented in the Roche Media Release.
05 Sep 2025 According to Genentech media release, data from this study presented at the 25th Euretina Congress in Paris, France.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com